Alkindi® is the first preparation of hydrocortisone specifically designed for and studied in children suffering from pediatric adrenal insufficiency (AI).
Alkindi® is a patented, oral, immediate-release formulation of hydrocortisone-containing granules in capsules for opening. that allows accurate age-appropriate dosing, especially in infants and children. This therapeutic approach has the potential to help young patients under the age of eighteen suffering from pediatric AI and congenital adrenal hyperplasia (CAH).
EffRx obtained the Swiss Marketing Authorization for Alkindi® as a replacement therapy for adrenal insufficiency in infants, children, and adolescents (from birth to less than eighteen years) in 2021. Alkindi® is now also available to patients in Switzerland, where around 200 children suffer from pediatric AI.
For more information,please refer to the medicinal product information published at www.swissmedicinfo.ch
Efmody® is a modified-release hydrocortisone therapy that addresses a critical need in the management of congenital adrenal hyperplasia (CAH), offering a new treatment opportunity for patients with this rare genetic condition.
EffRx has obtained from Swissmedic the Marketing Authorization for Efmody® and is currently seeking reimbursement from FOPH to enable the introduction to the market.
The approval and planned market launch of Efmody® in Switzerland is a testament to EffRx’s commitment to expanding access to essential therapies for rare conditions, and emphasizes its role in transforming patient care in the field of congenital adrenal hyperplasia.
For more information, please refer to the medicinal product information published at www.swissmedicinfo.ch
Miglustat Dipharma is an inhibitor of glucosylceramide synthase, the enzyme responsible for the first step in the synthesis of most glycolipids. The inhibitory action on glucosylceramide synthase forms the rationale for substrate reduction therapy in Gaucher disease type 1. Miglustat Dipharma is also indicated to reduce the progression of clinically relevant neurological symptoms in patients affected by Niemann-Pick type C disease, which are considered secondary to the abnormal accumulation of glycosphingolipids in neuronal and glial cells.1
EffRx is acting as Dipharma’s exclusive distributor for Miglustat Dipharma in Switzerland.
In Switzerland, EffRx Pharmaceuticals plays a pivotal role in ensuring that this medication is accessible to patients in need. The collaboration with Dipharma underscores our commitment to enhancing patient care and improving outcomes for those diagnosed with Gaucher disease or Niemann-Pick type C disease.
For more information, please refer to the medicinal product information published at www.swissmedicinfo.ch
Metopiron® is a fast-acting, reversible steroid synthesis inhibitor for patients with endogenous Cushing’s syndrome and offers flexible dosing with a favorable benefit-risk profile confirmed by four decades of experience..
For more information, please refer to the medicinal product information published at www.swissmedicinfo.ch
For over 60 years, Lysodren® has been the cornerstone of treatment for advanced adrenocortical carcinoma as the only approved therapy, helping to prolong patients’ lives through its dual action in controlling tumor growth and hormone secretion.
For more information, please refer to the medicinal product information published at www.swissmedicinfo.ch
